(+)-3-methyl-2-pyrrolidinone | 27948-40-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (+)-3-methyl-2-pyrrolidinone
• 英文别名: (R)-3-methylpyrrolidin-2-one；(3R)-3-methylpyrrolidin-2-one
• CAS: 27948-40-9
• 化学式: C₅H₉NO
• 分子量: 99.1326
• InChiKey: AOCWQPKHSMJWPL-SCSAIBSYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  7
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2933790090

反应信息

• 作为反应物：
  描述：

  (+)-3-methyl-2-pyrrolidinone 在 4-二甲氨基吡啶 、 lithium hydroxide 、 水 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 5.0h， 生成 (S)-4-((tert-butoxycarbonyl)amino)-2-methylbutanoic acid
  参考文献：
  名称：

  Enantioselective Preparation of γ ‐Amino Acids and γ ‐Lactams from Nitro Olefins and Carboxylic Acids, with the Valine‐Derived 4‐Isopropyl‐5,5‐diphenyl‐1,3‐oxazolidin‐2‐one as an Auxiliary

  摘要：

  DOI：

  10.1002/(sici)1522-2675(19991215)82:12<2365::aid-hlca2365>3.0.co;2-#
• 作为产物：
  描述：

  (R)-2-methyl-4-phthalimido-butyric acid 以62%的产率得到
  参考文献：
  名称：

  RINGDAHL B.; DAHLBOM R., ACTA PHARM. SUEC., 1978, 15, NO 4, 255-263

  摘要：

  DOI：

文献信息

• CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS
  申请人：ReSet Therapeutics, Inc.

  公开号：US20150284362A1

  公开（公告）日：2015-10-08

  The subject matter herein is directed to carbazole-containing amide, carbamate, and urea derivatives and pharmaceutically acceptable salts or hydrates thereof of structural formula I wherein the variable R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , A, D, E, G, J, L, M, Q, a, and b are accordingly described. Also provided are pharmaceutical compositions containing the compounds of formula I to treat a Cry-mediated disease or disorder, such as diabetes, complications associated with diabetes, Cushing's syndrome, NASH, NAFLD, asthma, and COPD.

  本文涉及含有咔唑基的酰胺、碳酸酯和脲衍生物，以及其结构式I中的药用可接受盐或水合物，其中变量R1、R2、R3、R4、R5、R6、R7、A、D、E、G、J、L、M、Q、a和b分别描述。还提供了含有式I化合物的药物组合物，用于治疗Cry介导的疾病或紊乱，如糖尿病、与糖尿病相关的并发症、库欣综合征、NASH、NAFLD、哮喘和COPD。
• [EN] HER2 MUTATION INHIBITORS<br/>[FR] INHIBITEURS DE MUTATION HER2
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2022003575A1

  公开（公告）日：2022-01-06

  This invention relates to compounds of Formula (I), and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein L1, L2, R1, R2, R3 and n are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.

  本发明涉及式(I)的化合物及其对映体，以及式(I)及其对映体的药用可接受盐，其中L1、L2、R1、R2、R3和n如本文所定义。本发明还涉及包括这些化合物和盐的药物组合物，以及利用这些化合物、盐和组合物治疗需要的受试者中的异常细胞生长，包括癌症的方法和用途。
• Optical Resolution of Cyclic Amides by Inclusion in Dehydrocholic Acid
  作者：Olga Bortolini、Marco Fogagnolo、Giancarlo Fantin、Alessandro Medici

  DOI：10.1246/cl.2003.206

  日期：2003.3

  Dehydrocholic acid serves as an effective chiral host for the resolution of several five-, six-, and seven-membered cyclic amides by inclusion.

  脱氢胆酸可作为有效的手性主体，通过包合拆分几种五元、六元和七元环酰胺。
• Separation of (S)-(−)-3-Methyl-2-pyrrolidinone as an Inclusion Complex with (R)-(+)-4,4′,6,6′-Tetrachloro-2,2′-bis(hydroxydiphenylmethyl)-1,1′-biphenyl Host and its X-ray Structural Study
  作者：Tanya le Roex、Luigi R. Nassimbeni、Fumio Toda

  DOI：10.1007/s10870-007-9312-8

  日期：2008.1

  By inclusion complexation with the chiral host compound (R)-(+)-4,4′,6,6′-tetrachloro-2,2′-bis(hydroxydiphenylmethyl)-1,1′-biphenyl, racemic 3-methyl-2-pyrrolidinone was resolved and its (S)-(−)-enantiomer was isolated as a 1:1 inclusion complex, which crystallises in the orthorhombic crystal system in the space group P212121 (a = 14.1163(2) Å, b = 14.7140(3) Å, c = 17.2025(3) Å). By the inclusion complexation, the keto–enol equilibrium of the guest was frozen and the keto-form was isolated in a pure form. By X-ray structural study of the complex, the guest molecule included was elucidated to be the keto-form and its absolute configuration was determined to be (S). By inclusion complexation with (R)-(+)-4,4′,6,6′-tetrachloro-2,2′-bis (hydroxydiphenylmethyl)-biphenyl, racemic 3-methyl-2-pyrrolidinone was resolved and its (S)-(−)-enantiomer isolated and in addition the keto–enol equilibrium of the guest was frozen and the keto-form isolated.

  通过与手性主体化合物(R)-(+)-4,4',6,6'-四氯-2,2'-双(羟基二苯基甲基)-1,1'-联苯的包合络合，得到外消旋3-甲基- 2-吡咯烷酮被解析，其 (S)-(−)-对映体被分离为 1:1 包合物，在空间群 P212121 的斜方晶系中结晶 (a = 14.1163(2) Å，b = 14.7140 (3) Å, c = 17.2025(3) Å)。通过包合络合，客体的酮-烯醇平衡被冻结，并且酮形式以纯形式分离。通过对该配合物的X射线结构研究，确定所包含的客体分子为酮型，其绝对构型确定为(S)。通过与(R)-(+)-4,4',6,6'-四氯-2,2'-双(羟基二苯基甲基)-联苯的包合络合，拆分出外消旋3-甲基-2-吡咯烷酮，并得到其(S )-(−)-对映异构体被分离，此外客体的酮-烯醇平衡被冻结并分离出酮形式。
• Asymmetric synthesis of 3-substituted pyrrolidones via α-alkylation of a chiral non-racemic γ-lactam
  作者：Isabelle Baussanne、Catherine Travers、Jacques Royer

  DOI：10.1016/s0957-4166(98)00024-x

  日期：1998.3

  3-Alkyl pyrrolidones 9 were synthesized in good yield and high diastereoselectivity by oc-alkylation of the new chiral non-racemic lactam 8 derived from (R)-(-)-phenylglycinol. After debenzylation and introduction of an electron-withdrawing group, 3-methylpyrrolidone 10 is easily hydrolyzed in a basic medium to produce gamma-aminobutyric acid (GABA) analogue 13. (C) 1998 Elsevier Science Ltd. All rights reserved.